← All trials
NCT06032000
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 6, 2023
- Primary completion
- Mar 31, 2024
- Completion date
- Feb 28, 2025
- First posted
- Sep 11, 2023
- Last posted
- Dec 7, 2023
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Lemonex Inc.Lead sponsor
- Lemonex Inc.Study director
- Lemonex Inc.Official
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.